TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11356997

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular-intensity anticoagulation (target INR values: 2.5-3.5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-intensity anticoagulation (target INR values: 1.1-1.6)
Number of subjects: 0
Study: 8794442

Group type: EXPERIMENTAL
Intervention: E2-DG (1.5 mg E2 for 24 days with 0.15 mg DG for the last 12 days followed by 1 placebo tablet for 4 days)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: E2-NETA (2 mg E2 for 22 days with 1 mg NETA for the last 10 days followed by 1 mg E2 for 6 days)
Number of subjects: 310

Group type: COMPARATOR
Intervention: E2-DG
Number of subjects: 310

Group type: COMPARATOR
Intervention: E2-NETA
Number of subjects: 310
Study: 1377306

Group type: COMPARATOR
Intervention: Nitrendipine (20 mg single dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg daily for 2 months)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6740419

Group type: EXPERIMENTAL
Intervention: Theo-dur
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Euphyllin Retard
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcophyllin syrup
Number of subjects: 0
Study: 3080291

Group type: EXPERIMENTAL
Intervention: Misoprostol 400 micrograms bid
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms bid
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: All groups (including antacid use)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Misoprostol 400 micrograms
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms
Number of subjects: 330
Study: 31262680

Group type: EXPERIMENTAL
Intervention: CAD/CAM splints and patient‐specific osteosynthesis for maxillary positioning (Group 1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Occlusal wafers fabricated on a semi‐adjustable articulator (Group 2)
Number of subjects: 18
Study: 28786301

Group type: EXPERIMENTAL
Intervention: 120 kVp, 10 mAs, with MBIR
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 100 kVp, 15 mAs, with MBIR
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 100 kVp, 10 mAs, with MBIR
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 100 kVp, 5 mAs, with MBIR
Number of subjects: 120

Group type: COMPARATOR
Intervention: 120 kVp, 25 mAs, with FBP reconstruction
Number of subjects: 120
Study: 26888726

Group type: EXPERIMENTAL
Intervention: Qualitative focus group discussions among biomedical scientists
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Senior scientists
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: PhD students and postdoctoral fellows
Number of subjects: 3
Study: 26118148

Group type: EXPERIMENTAL
Intervention: FSS-AA T2DM (Family Support Scale Adapted for African American women with T2DM)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: FSS-AA T2DM
Number of subjects: 200
Study: 23018440

Group type: EXPERIMENTAL
Intervention: Drug conservation group
Number of subjects: 2206

Group type: COMPARATOR
Intervention: Viral suppression group
Number of subjects: 2206

Group type: EXPERIMENTAL
Intervention: Drug conservation participants on fully suppressive ART
Number of subjects: 2206

Group type: EXPERIMENTAL
Intervention: Drug conservation participants who resumed ART
Number of subjects: 2206
Study: 20197480

Group type: EXPERIMENTAL
Intervention: (1)H-MRSI-DCEMR examination and targeted samples on suspicious areas
Number of subjects: 180

Group type: COMPARATOR
Intervention: Second random prostate biopsy
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: MRSI
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: DCEMR
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: MRSI plus DCEMR
Number of subjects: 180
Study: 18230235

Group type: EXPERIMENTAL
Intervention: Written emotional disclosure (WED)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxation training (RT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control writing
Number of subjects: 0
Study: 16679825

Group type: EXPERIMENTAL
Intervention: Group 1: Lycopene (3 mg/day), Lutein (3 mg/day), Beta-carotene (4.8 mg/day), Alpha-tocopherol (10 mg/day), Selenium (75 microg/day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Group 2: Lycopene (6 mg/day), Beta-carotene (4.8 mg/day), Alpha-tocopherol (10 mg/day), Selenium (75 microg/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo Control (Group 3)
Number of subjects: 39
Study: 12564742

Group type: EXPERIMENTAL
Intervention: talinolol (100 mg)
Number of subjects: 198

Group type: COMPARATOR
Intervention: atenolol (50 mg)
Number of subjects: 198
Study: 11200748

Group type: EXPERIMENTAL
Intervention: BAL fluid from s.A in sarcoidosis patients (3.18 pg/ml)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: BAL fluid from s.B in sarcoidosis patients (2.64 pg/ml)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: BAL fluid from s.A in sarcoidosis patients (1.01 pg/ml)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: BAL fluid from s.B in sarcoidosis patients (0.95 pg/ml)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: BAL fluid from s.A in ND group (3.77 pg/ml)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: BAL fluid from s.A in active sarcoidosis
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: BAL fluid from s.A in patients with indications to therapy (1.44 pg/ml)
Number of subjects: 28
Study: 8825532

Group type: EXPERIMENTAL
Intervention: 20 mg piroxicam given two hours preoperatively
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo given two hours preoperatively
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 mg piroxicam given immediately before induction of anaesthesia
Number of subjects: 60
Study: 1451729

Group type: EXPERIMENTAL
Intervention: Quinidine (50 mg orally)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Flecainide acetate (150 mg)
Number of subjects: 6
Study: 6371535

Group type: EXPERIMENTAL
Intervention: Dipyridamole (225 mg per day) and Aspirin (975 mg per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dipyridamole and Aspirin
Number of subjects: 40
Study: 30254135

Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg three times a day for 2 weeks, then 200 mg three times a day for a further 2 weeks
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 27177869

Group type: EXPERIMENTAL
Intervention: Skype-based online video chats and WhatsApp messages
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 18
Study: 25463450

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (DTI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Higher fractional anisotropy of the left superior longitudinal fasciculus (SLF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Psychomotor vigilance test (PVT)
Number of subjects: 30
Study: 22832637

Group type: EXPERIMENTAL
Intervention: Multifactorial fall-and-fracture risk assessment and management program including intensive targeted exercise
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care in a general geriatric unit
Number of subjects: 122
Study: 21232664

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAT) - aspirin, clopidogrel, and cilostazol for 6 months
Number of subjects: 960

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAT) - aspirin and clopidogrel for 6 months
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAT) - aspirin, clopidogrel, and cilostazol at discharge
Number of subjects: 960

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAT) - aspirin and clopidogrel at discharge
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAT) - aspirin, clopidogrel, and cilostazol at 6 months
Number of subjects: 960

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAT) - aspirin and clopidogrel at 6 months
Number of subjects: 960
Study: 19235536

Group type: EXPERIMENTAL
Intervention: Protein C Concentrate (PCC) replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Symptomatic therapies
Number of subjects: 0
Study: 17028293

Group type: EXPERIMENTAL
Intervention: Epoetin beta (300 U/kg), administered three times weekly starting 10 to 14 days before and continuing throughout radiotherapy.
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo, administered under double-blind conditions.
Number of subjects: 154
Study: 15152816

Group type: EXPERIMENTAL
Intervention: SRP plus minocycline microspheres
Number of subjects: 499

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 499
Study: 12793949

Group type: EXPERIMENTAL
Intervention: Airway Pressure Release Ventilation (APRV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Volume-Controlled Synchronized Intermittent Mechanical Ventilation (SIMV)
Number of subjects: 0
Study: 9588614

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Morphologic fitness
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Strength fitness
Number of subjects: 161
Study: 8019119

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 59
Study: 2590619

Group type: EXPERIMENTAL
Intervention: Psorin (low concentration dithranol and coal tar)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Alphosyl (alcoholic coal tar extract and allantoin)
Number of subjects: 23
Study: 1020902

Group type: EXPERIMENTAL
Intervention: 5 000 units of heparin preoperatively and every 12 hours following the operation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline at the corresponding time
Number of subjects: 10
Study: 31630117

Group type: EXPERIMENTAL
Intervention: Programmed treatment group (3 mg/kg IFX until week 6, then dose adjusted based on baseline TNF-α levels until week 54)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Standard treatment group (3 mg/kg IFX)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Programmed treatment group
Number of subjects: 337

Group type: COMPARATOR
Intervention: Standard treatment group
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 337
Study: 31744523

Group type: EXPERIMENTAL
Intervention: Newly built birthing room designed with a person‐centred approach and physical aspects (light, silencer, media installation, bathtub, birth support tools)
Number of subjects: 1274

Group type: COMPARATOR
Intervention: Regular room (control group)
Number of subjects: 1274

Group type: EXPERIMENTAL
Intervention: Newly built birthing room
Number of subjects: 1274
Study: 27469171

Group type: EXPERIMENTAL
Intervention: Tapered interference fit (TIF) implants
Number of subjects: 15

Group type: COMPARATOR
Intervention: Taper-integrated screwed-in (TIS) implants
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both TIF and TIS implants
Number of subjects: 15
Study: 25582816

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (bilateral BL32 and BL33 acupoints, electrical pulse generator, twice a week for 7 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Medical treatment (levofloxacin 500 mg daily and ibuprofen 200 mg twice a day for 6 weeks)
Number of subjects: 54
Study: 23737921

Group type: EXPERIMENTAL
Intervention: Standardized peer-teaching training of practical competences for 45 minutes including surgical scrubbing according to EN1500
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group received training after the test
Number of subjects: 161

Group type: COMPARATOR
Intervention: Clinical reference groups (surgeons)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Clinical reference groups (scrub nurses)
Number of subjects: 161
Study: 21903477

Group type: EXPERIMENTAL
Intervention: Cortivazol 3.75 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 18930474

Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg/d for six weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16733171

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (n = 35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional coronary artery bypass grafting (n = 35)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Histological analysis
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Age and left atrial enlargement
Number of subjects: 70
Study: 14660503

Group type: EXPERIMENTAL
Intervention: Unilateral knee extensor resistance exercise (ULRE) performed two or three times weekly.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Unilateral lower limb unloading (UL) with no training.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Unilateral knee extensor resistance exercise (ULRE)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Unilateral lower limb unloading (UL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Unilateral lower limb unloading (UL) and Unilateral knee extensor resistance exercise (ULRE)
Number of subjects: 21
Study: 11746863

Group type: EXPERIMENTAL
Intervention: Pycnogenol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 8996712

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) plus buspirone
Number of subjects: 77

Group type: COMPARATOR
Intervention: Cognitive behaviour therapy (CBT) plus placebo
Number of subjects: 77
Study: 8241011

Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg as a bolus intravenously, followed by an infusion of 0.04 mg/kg/hr)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 3310369

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA), 50 mg twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29359575

Group type: EXPERIMENTAL
Intervention: SAR-Lis
Number of subjects: 27

Group type: COMPARATOR
Intervention: Ly-Lis
Number of subjects: 27
Study: 28342214

Group type: EXPERIMENTAL
Intervention: rtfMRI‐NF of right inferior prefrontal cortex (rIFG)
Number of subjects: 31

Group type: COMPARATOR
Intervention: rtfMRI‐NF of left parahippocampal gyrus (lPHG)
Number of subjects: 31
Study: 23359072

Group type: EXPERIMENTAL
Intervention: Active Living Every Day (ALED) intervention for 20 weeks
Number of subjects: 354

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 354
Study: 23525499

Group type: EXPERIMENTAL
Intervention: rIPC alone in rabbit model
Number of subjects: 24

Group type: COMPARATOR
Intervention: rIPC after ALDH-2 inhibitor cyanamide in rabbit model
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: rIPC in wild-type individuals
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: rIPC in carriers of Glu504Lys polymorphism
Number of subjects: 24

Group type: COMPARATOR
Intervention: rIPC with placebo in double-blind study
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: rIPC with disulfiram (600 mg od)
Number of subjects: 24
Study: 20888162

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 3006

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 3006

Group type: EXPERIMENTAL
Intervention: Routine angiographic follow-up
Number of subjects: 3006
Study: 18239561

Group type: EXPERIMENTAL
Intervention: Acute exercise (three different intensity treatments)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Moderate (50% VO(2)) and high (75% VO(2)) intensity acute exercise
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 16
Study: 16328464

Group type: EXPERIMENTAL
Intervention: Continuous Active Motion (CAM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous Passive Motion (CPM)
Number of subjects: 60
Study: 12712486

Group type: EXPERIMENTAL
Intervention: aprepitant 125 mg on Day 1 and 80 mg on Days 2-5
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: aprepitant 40 mg on Day 1 and 25 mg on Days 2-5
Number of subjects: 376

Group type: COMPARATOR
Intervention: standard therapy (intravenous ondansetron plus oral dexamethasone)
Number of subjects: 376
Study: 10914752

Group type: EXPERIMENTAL
Intervention: 10% dextrose infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 10
Study: 8819106

Group type: EXPERIMENTAL
Intervention: Mitogen-stimulated lymphocytes from elderly subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mitogen-stimulated lymphocytes from young individuals
Number of subjects: 0
Study: 8158512

Group type: EXPERIMENTAL
Intervention: Group A: Oral hygiene instructions with scaling and root planing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group B: Oral hygiene instructions without subgingival scaling and root planing
Number of subjects: 30
Study: 3202452

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg twice a day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 29941911

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise (NSE)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Waiting list (WL)
Number of subjects: 26
Study: 28692014

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) training
Number of subjects: 23
Study: 25280244

Group type: EXPERIMENTAL
Intervention: Guided individualised feedback (written or verbal guidance on interpreting a graphical summary profile)
Number of subjects: 129
Study: 22985013

Group type: EXPERIMENTAL
Intervention: Acute exercise for 15 minutes
Number of subjects: 81

Group type: COMPARATOR
Intervention: Quiet rest (Control)
Number of subjects: 81
Study: 21466388

Group type: EXPERIMENTAL
Intervention: Losartan added to standard care
Number of subjects: 500000000

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 500000000
Study: 19084786

Group type: EXPERIMENTAL
Intervention: Discussion of maternal stress during pediatric primary care visits
Number of subjects: 747
Study: 16793562

Group type: EXPERIMENTAL
Intervention: Niacin extended-release/lovastatin (500/20 mg) once daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Simvastatin (20 mg) once daily
Number of subjects: 70
Study: 12925473

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 10
Study: 10929338

Group type: EXPERIMENTAL
Intervention: Pulsatile lavage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Syringe lavage
Number of subjects: 0
Study: 7472905

Group type: EXPERIMENTAL
Intervention: Vitamin D intake of 200 IU/day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Vitamin D intake of 400 IU/day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Vitamin D intake of 800 IU/day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Follow-up after earlier manipulation of vitamin D intake
Number of subjects: 62
Study: 2179366

Group type: EXPERIMENTAL
Intervention: Long-term continuous subcutaneous infusion of large doses of salbutamol (greater than 14 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intermittent nebulization of salbutamol
Number of subjects: 10
Study: 6986067

Group type: EXPERIMENTAL
Intervention: Cefadroxil 2,000 mg once daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cefadroxil 1,000 mg once daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cefadroxil 1,000 mg twice daily
Number of subjects: 100
Study: 30597803

Group type: EXPERIMENTAL
Intervention: 2 mg L-1 flumequine (FLU)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (absence of FLU)
Number of subjects: 62
Study: 28906414

Group type: EXPERIMENTAL
Intervention: Lidocaine jelly applied to the tapered cuff of the endotracheal tube (ETT)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Normal saline applied to the tapered cuff of the endotracheal tube (ETT)
Number of subjects: 208
Study: 26255764

Group type: EXPERIMENTAL
Intervention: 6 weekly fractions (fx/w) of radiotherapy
Number of subjects: 694

Group type: COMPARATOR
Intervention: 5 weekly fractions (fx/w) of radiotherapy
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 694
Study: 23369174

Group type: EXPERIMENTAL
Intervention: Sites group (treatment)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 21844080

Group type: EXPERIMENTAL
Intervention: Exercise Electrocardiography (ETT)
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: Exercise Myocardial Perfusion Imaging (MPI)
Number of subjects: 824
Study: 19709113

Group type: EXPERIMENTAL
Intervention: 0.2% (w/v) CPP‐ACP in bovine milk
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.3% (w/v) CPP‐ACP in bovine milk
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control milk (no added CPP‐ACP)
Number of subjects: 10
Study: 18087797

Group type: EXPERIMENTAL
Intervention: Buprenorphine 16 mg + naloxone 4 mg/day
Number of subjects: 326

Group type: COMPARATOR
Intervention: Buprenorphine 16 mg + placebo
Number of subjects: 326
Study: 15533377

Group type: EXPERIMENTAL
Intervention: Modified GnRH antagonist protocol with 75 IU recombinant FSH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard long GnRH agonist protocol
Number of subjects: 0
Study: 11552215

Group type: EXPERIMENTAL
Intervention: Aprotinin infusion (1,000,000-KIU loading dose, followed by 250,000-KIU/h infusion during surgery)
Number of subjects: 63
Study: 9778719

Group type: EXPERIMENTAL
Intervention: propofol/alfentanil
Number of subjects: 36

Group type: COMPARATOR
Intervention: midazolam/fentanyl
Number of subjects: 36
Study: 7709944

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g elemental calcium)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 2691233

Group type: EXPERIMENTAL
Intervention: Tetracycline (500 mg four times daily for a week)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no tetracycline)
Number of subjects: 140
Study: 4593780

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 14
Study: 29681188

Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 64

Group type: COMPARATOR
Intervention: Myofascial release
Number of subjects: 64
Study: 28043731

Group type: EXPERIMENTAL
Intervention: Acetazolamide (250mg) and Hydrochlorothiazide (50mg) daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Furosemide (40mg) and Hydrochlorothiazide (50mg) daily
Number of subjects: 20